Biotech Values

[DewDiligence]

>>
As I understand it, we can expect study arms as follows:
1)ATryn active study arm with 17 new patients from Europe and USA;
2)Historical control arm with 35 preselected patients from Europe and USA.
3) A total of 31 patients from USA and Europe will be compared to 35 historical controls from USA and Europe.
<<

Correct.

>>It is indeed a small coup, Dew, to be allowed to pool data and stack the odds for a favorable outcome with existing data from a similar, positive study. Maybe we should attempt to verify that Cox meant what he said.<<

Dr. Cox paused for a moment as though considering the ramifications, so I assume that he did fully understand the question. I plan to follow up with Tom Newberry to be sure.